Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's ...
Eli Lilly (LLY) reduced its fourth-quarter sales guidance by 5%, lowering expectations to $13.5 billion. This figure is $400 ...
Lilly in August began sending cease-and-desist letters to telehealth companies, wellness centers and medical spas selling compounded versions of Zepbound and Mounjaro. The company has also filed ...
This top healthcare company trades at 13 times forward earnings. It has a diverse portfolio of products, yields 3.6% at the ...
Eli Lilly estimates that is about 15-20 million ... Obstructive sleep apnea isn’t just an inconvenience, it’s a serious medical condition that impairs breathing and sleep quality.
beating the performance of the Medical sector with its loss of 3.78% and the S&P 500's gain of 0.22%. The investment community will be closely monitoring the performance of Eli Lilly in its ...
Sleep apnea, a sleep disorder typically managed with a medical device that aids in breathing, now has its first FDA-approved drug therapy, an Eli Lilly medicine initially developed as a treatment ...
Zacks.com on MSN8d
Why the Market Dipped But Eli Lilly (LLY) Gained TodayIn the latest trading session, Eli Lilly (LLY) closed at $773.29, marking a +1.07% move from the previous day.
Eli Lilly & Co. (NYSE: LLY) is a major global pharmaceutical company in the medical sector. The company made headlines with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback